Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  isotretinoin
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: ACNS0332, NCI-2009-00336, CDR0000511991, COG-ACNS0332, NCT00392327
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
Lenalidomide and Dinutuximab with or without Isotretinoin in Treating Younger Patients with Refractory or Recurrent Neuroblastoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: NANT 2011-04, NCI-2012-02011, CDR0000741991, N2011-04, NANT 11-04, PNANT N2011-04_A14PAMDREVW01, NANT N2011-04, NCT01711554
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients with Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy with Isotretinoin
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: ANBL09P1, NCI-2011-01745, CDR0000682629, COG-ANBL09P1, NCT01175356
Standard of Care High-Dose Chemotherapy and Stem Cell Transplant in Treating Younger Patients with Neuroblastoma
Phase: No phase specified
Type: Treatment
Age: 30 and under
Trial IDs: MT2011-11C, NCI-2013-02264, 1112M07741, 2011SC072, NCT01526603
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with High-Risk Neuroblastoma
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: 13-260, NCI-2014-00815, NCT02100930
Start Over